Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinyl-Coa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.87 |
| ▸ | CHAT | P28329 | 2/20 | 0.83 |
| ▸ | EP300 | Q09472 | 3/20 | 0.82 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.82 |
| ▸ | AURKA | O14965 | 2/20 | 0.82 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.82 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinyl-Coa SCHEMBL4364428 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL28138807 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL30927108 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL50744 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL4360979 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL4360968 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL28059593 | 1.00 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL1643484 | 0.99 | NAA50 (0.86) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL31108060 | 0.99 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Succinyl-Coa SCHEMBL5529148 | 0.98 | NAA50 (0.84) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041378-A1 | METHODS OF AND DEVICES/APPARATUS FOR DETECTING, TRIGGERING, AND USING CELL-TO-CELL COMMUNICATION | IMMUNOLIGHT, LLC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260041378-A1 | METHODS OF AND DEVICES/APPARATUS FOR DETECTING, TRIGGERING, AND USING CELL-TO-CELL COMMUNICATION | NFATC1, STAT3, PIEZO1 | NAA50 4679/4885CHAT 208/4885EP300 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.